SCHEMBL4191801

SCHEMBL4191801

COc1ccccc1Nc1ccc(-c2coc3cc(O)ccc3c2=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.67
ALDH1A1 P00352 11/20 0.67
HSD17B10 Q99714 10/20 0.67
HPGD P15428 10/20 0.67
SMN1; SMN2 Q16637 6/20 0.67
CYP3A4 P08684 5/20 0.67
USP2 O75604 2/20 0.67
GLA P06280 1/20 0.67
RAB9A P51151 7/20 0.64
MAPT P10636 6/20 0.64
NPC1 O15118 6/20 0.64
TP53 P04637 4/20 0.64
MAPK1 P28482 1/20 0.64
HDAC6 Q9UBN7 3/20 0.64
CYP2D6 P10635 2/20 0.64
CYP2C9 P11712 2/20 0.64
MAOA P21397 2/20 0.64
MAOB P27338 2/20 0.64
CYP2C19 P33261 2/20 0.64
MEN1 O00255 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4182239 0.86 KDM4E (0.65) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL4175335 0.84 KDM4E (0.86) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL4173475 0.83 KDM4E (0.78) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL234467 0.81 KDM4E (1.00) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL30991585 0.81 KDM4E (1.00) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL13774692 0.79 KDM4E (0.67) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
Cladrin SCHEMBL738092 0.79 KDM4E (1.00) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
Formononetin SCHEMBL29361145 0.78 KDM4E (1.00) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
Formononetin SCHEMBL15271536 0.78 KDM4E (1.00) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
Formononetin SCHEMBL62915 0.78 KDM4E (1.00) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192152-A1 Novel Antigiardial Agents and Methods of Use Thereof UNIVERSITY OF MISSISSIPPI 2009-07-30 US disclosed
US-20090192152-A1 Novel Antigiardial Agents and Methods of Use Thereof UNIVERSITY OF MISSISSIPPI 2009-07-30 US disclosed
US-7468445-B2 Antigiardial agents and use thereof UNIVERSITY OF MISSISSIPPI (US) 2008-12-23 US disclosed
US-7468445-B2 Antigiardial agents and use thereof UNIVERSITY OF MISSISSIPPI (US) 2008-12-23 US disclosed
US-20060106091-A1 Antigiardial agents and use thereof THE UNIVERSITY OF MISSISSIPPI 2006-05-18 US disclosed
WO-2004014886-A1 ANTIGIARDIAL AGENTS AND USE THEREOF UNIVERSITY OF MISSISSIPPI (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106091-A1 Antigiardial agents and use thereof GPER1, ENPP2, ALPI KDM4E 2433/4885ALDH1A1 2026/4885HSD17B10 1958/4885
US-20090192152-A1 Novel Antigiardial Agents and Methods of Use Thereof ENPP2, GPER1, ALPI KDM4E 2954/4885ALDH1A1 2472/4885HSD17B10 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.